Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 8 | 2018 | 41 | 2.270 |
Why?
|
| Alzheimer Disease | 7 | 2022 | 26 | 1.920 |
Why?
|
| Inpatients | 3 | 2020 | 17 | 1.220 |
Why?
|
| Dementia | 3 | 2018 | 13 | 1.130 |
Why?
|
| Insulin Resistance | 2 | 2021 | 63 | 0.720 |
Why?
|
| Hospitalization | 3 | 2018 | 106 | 0.710 |
Why?
|
| Humans | 22 | 2022 | 4931 | 0.710 |
Why?
|
| Aged | 13 | 2020 | 1188 | 0.680 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2020 | 3 | 0.670 |
Why?
|
| Neoplasms | 1 | 2020 | 66 | 0.630 |
Why?
|
| Male | 16 | 2021 | 2620 | 0.620 |
Why?
|
| Female | 17 | 2021 | 2964 | 0.610 |
Why?
|
| Cognition | 2 | 2021 | 23 | 0.600 |
Why?
|
| Life Style | 2 | 2022 | 44 | 0.570 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 12 | 0.560 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 407 | 0.540 |
Why?
|
| Acute Coronary Syndrome | 1 | 2016 | 12 | 0.520 |
Why?
|
| Seizures | 1 | 2014 | 14 | 0.440 |
Why?
|
| United States | 7 | 2020 | 764 | 0.440 |
Why?
|
| Risk Factors | 6 | 2022 | 593 | 0.440 |
Why?
|
| Hypertension | 5 | 2018 | 123 | 0.420 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2012 | 5 | 0.390 |
Why?
|
| Atrial Fibrillation | 3 | 2016 | 14 | 0.360 |
Why?
|
| Diet | 1 | 2012 | 95 | 0.360 |
Why?
|
| Retrospective Studies | 4 | 2018 | 513 | 0.360 |
Why?
|
| Comorbidity | 5 | 2018 | 123 | 0.340 |
Why?
|
| Middle Aged | 10 | 2021 | 1544 | 0.340 |
Why?
|
| Communication | 2 | 2021 | 23 | 0.300 |
Why?
|
| Databases, Factual | 2 | 2020 | 60 | 0.280 |
Why?
|
| Prevalence | 3 | 2018 | 184 | 0.270 |
Why?
|
| Leisure Activities | 2 | 2017 | 3 | 0.260 |
Why?
|
| Exercise | 2 | 2017 | 41 | 0.250 |
Why?
|
| Hospital Mortality | 2 | 2015 | 30 | 0.240 |
Why?
|
| Algorithms | 2 | 2016 | 69 | 0.200 |
Why?
|
| Amyloid | 1 | 2021 | 2 | 0.190 |
Why?
|
| Retinal Vein | 1 | 2021 | 2 | 0.190 |
Why?
|
| Memory Disorders | 1 | 2021 | 5 | 0.190 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 146 | 0.180 |
Why?
|
| Dysbiosis | 1 | 2021 | 8 | 0.180 |
Why?
|
| Logistic Models | 2 | 2018 | 117 | 0.170 |
Why?
|
| Length of Stay | 1 | 2020 | 34 | 0.160 |
Why?
|
| Neuropsychological Tests | 2 | 2017 | 9 | 0.160 |
Why?
|
| Time Factors | 2 | 2018 | 245 | 0.150 |
Why?
|
| Amnesia, Transient Global | 1 | 2018 | 3 | 0.150 |
Why?
|
| Migraine Disorders | 1 | 2018 | 10 | 0.150 |
Why?
|
| Hyperlipidemias | 1 | 2018 | 15 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 8 | 0.150 |
Why?
|
| Cerebral Hemorrhage | 1 | 2018 | 4 | 0.150 |
Why?
|
| Brain Ischemia | 1 | 2018 | 9 | 0.140 |
Why?
|
| Brain | 2 | 2021 | 78 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 67 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 258 | 0.140 |
Why?
|
| Health Surveys | 1 | 2017 | 55 | 0.140 |
Why?
|
| Sex Factors | 1 | 2018 | 120 | 0.140 |
Why?
|
| Incidence | 2 | 2017 | 141 | 0.140 |
Why?
|
| Nutrition Surveys | 1 | 2017 | 47 | 0.140 |
Why?
|
| Diabetes Mellitus | 2 | 2016 | 170 | 0.130 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2016 | 2 | 0.130 |
Why?
|
| Angina, Unstable | 1 | 2016 | 3 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 32 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 358 | 0.130 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2016 | 11 | 0.130 |
Why?
|
| Dementia, Vascular | 1 | 2016 | 3 | 0.130 |
Why?
|
| Heart Failure | 1 | 2016 | 47 | 0.120 |
Why?
|
| Hypesthesia | 1 | 2015 | 1 | 0.120 |
Why?
|
| Face | 1 | 2015 | 3 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 76 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2015 | 15 | 0.120 |
Why?
|
| Primary Prevention | 1 | 2015 | 21 | 0.120 |
Why?
|
| Mortality | 1 | 2015 | 31 | 0.120 |
Why?
|
| Health Behavior | 1 | 2015 | 43 | 0.120 |
Why?
|
| Social Networking | 1 | 2014 | 4 | 0.110 |
Why?
|
| Women | 1 | 2014 | 4 | 0.110 |
Why?
|
| Community Health Workers | 1 | 2014 | 13 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2015 | 127 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 55 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 92 | 0.110 |
Why?
|
| Age Factors | 1 | 2014 | 152 | 0.110 |
Why?
|
| Lewy Body Disease | 1 | 2013 | 1 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 154 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 2012 | 28 | 0.100 |
Why?
|
| Adult | 4 | 2018 | 1402 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2009 | 41 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 276 | 0.090 |
Why?
|
| Evoked Potentials | 1 | 2009 | 1 | 0.080 |
Why?
|
| Nerve Net | 1 | 2009 | 3 | 0.080 |
Why?
|
| Task Performance and Analysis | 1 | 2009 | 4 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 5 | 0.080 |
Why?
|
| Temporal Lobe | 1 | 2008 | 4 | 0.070 |
Why?
|
| Cerebrovascular Circulation | 1 | 2008 | 5 | 0.070 |
Why?
|
| Oxygen | 1 | 2008 | 33 | 0.070 |
Why?
|
| Antiparkinson Agents | 1 | 2003 | 1 | 0.050 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2003 | 1 | 0.050 |
Why?
|
| Parkinson Disease | 1 | 2003 | 5 | 0.050 |
Why?
|
| Purines | 1 | 2003 | 10 | 0.050 |
Why?
|
| Risk | 2 | 2017 | 39 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2015 | 162 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2021 | 53 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2021 | 4 | 0.050 |
Why?
|
| American Heart Association | 1 | 2017 | 1 | 0.040 |
Why?
|
| School Teachers | 1 | 2017 | 2 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2017 | 13 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 77 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 26 | 0.030 |
Why?
|
| California | 1 | 2017 | 161 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 202 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 179 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 6 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 35 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 39 | 0.030 |
Why?
|
| Depression | 1 | 2016 | 97 | 0.030 |
Why?
|
| Smoking | 1 | 2015 | 59 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 73 | 0.030 |
Why?
|
| Women's Rights | 1 | 2014 | 3 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 146 | 0.030 |
Why?
|
| Women's Health | 1 | 2014 | 19 | 0.030 |
Why?
|
| Program Development | 1 | 2014 | 28 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2015 | 229 | 0.030 |
Why?
|
| Autopsy | 1 | 2013 | 3 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 9 | 0.030 |
Why?
|
| Obesity | 1 | 2015 | 189 | 0.030 |
Why?
|
| African Americans | 1 | 2015 | 256 | 0.020 |
Why?
|
| Rest | 1 | 2009 | 2 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2009 | 3 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 45 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 66 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 83 | 0.020 |
Why?
|
| Apolipoprotein E4 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Family Health | 1 | 2008 | 5 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 14 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 34 | 0.020 |
Why?
|
| Carbidopa | 1 | 2003 | 1 | 0.010 |
Why?
|
| Levodopa | 1 | 2003 | 1 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2003 | 22 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 15 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2003 | 36 | 0.010 |
Why?
|
| Motor Activity | 1 | 2003 | 24 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 81 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 126 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2003 | 402 | 0.010 |
Why?
|